2018 saw a breakthrough in the field of RNA interference (RNAi), when the US FDA approved the first drug using this gene-silencing mechanism. Five years and five more approved drugs later ...

The final word in target validation is to reintroduce an RNAi-resistant version of the target gene product into depleted cells and show recovery of function. This can be challenging for large sets ...

Alnylam Pharmaceuticals exceeded Wall Street's expectations with strong revenue growth and significant commercial progress.

While there are RNAi products on the marketplace, with Alnylam becoming the first company to get a product approved in 2018, it is difficult to get this class of drug distributed through the brain ...

Scientists seek innovative approaches to address this health crisis, some of which are therapeutics poised to treat CVD in new ways. RNA interference (RNAi) therapeutics silence genes, disrupting the ...

ALNY reports better-than-expected fourth-quarter results as both earnings and revenues beat estimates driven by higher ...

Her writing focuses on gene editing technology, cell and gene therapies, and the regulatory space. View Full Profile. Learn about our Editorial Policies. The natural RNAi mechanism can be directed by ...